Clinical Study for Topical Lupeol in Acne
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02205892|
Recruitment Status : Completed
First Posted : July 31, 2014
Last Update Posted : September 29, 2014
|Condition or disease||Intervention/treatment||Phase|
|Acne||Drug: Lupeol Drug: Placebo vehicle||Not Applicable|
To investigate the clinical efficacy and tolerability of lupeol for the treatment of facial acne, we conducted a small-scale, randomized, double-blinded, split-face clinical trial over the course of 4 weeks. Fifteen of 16 enrolled patients completed the study, in which affected areas on half each patient's face were treated with 2% lupeol twice daily while the other side of the face was treated with a vehicle control. Clinical visits were scheduled at baseline and at 2 and 4 weeks. The primary outcome of the study was the percent change in inflammatory lesions (papules, pustules, and nodules) at 4 weeks. The secondary outcomes were the percent change in non-inflammatory lesions (open and closed comedones) and the change in the Leeds revised acne grading system score at 4 weeks. Adverse events (AEs) were defined as all unintended and harmful signs or symptoms; these were assessed by both patients' self-reporting and physicians' skin examination at each visit. Results were analyzed using intent to treat (ITT) groups. The per-protocol (PP) population consisted of the 15 patients who did not have any major protocol deviations. Last observation carried forward (LOCF) analysis was used to evaluate the primary and secondary outcomes.
** Randomization and blindness process **
At the time of initial presentation, an evaluation of acne severity was performed using both individual counts of inflammatory and non-inflammatory acne lesions and an assessment of the Leeds revised acne grading system score. Then, patients were randomly assigned to either left- or right-sided lupeol application, with the other side of the face assigned to vehicle-control application. A simple random allocation sequence was created using computer-based random number generators with a block size of 4. All dermatologists participating in outcome assessments, a physician assistant managing trial enrollment and administration, medical statisticians analyzing the data, and patients were blinded to the assignments. Randomization codes were strictly secured in a safe in the administration office of the clinical research center until data entry was complete. The integrity of the blinding was ensured by packaging the study- and control products in identical tubes and by requiring a third party (other than the investigator/evaluator) to dispense the medication. In addition, both topical agents were identical in color and odor.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Clinical Study for the Effectiveness and Safety of Topical Lupeol in Mild to Moderate Acne|
|Study Start Date :||August 2014|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||September 2014|
|Active Comparator: Lupeol||
Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
|Placebo Comparator: Vehicle||
Drug: Placebo vehicle
Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
- Percent change of inflammatory acne lesion counts [ Time Frame: 4 week ]
- Percent change of non-inflammatory acne lesion counts [ Time Frame: 4 week ]
- Change of Leeds revised grade [ Time Frame: 4 week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02205892
|Korea, Republic of|
|Seoul National University Department of Dermatology|
|Seoul, Korea, Republic of, 110-744|
|Principal Investigator:||Dae Hun Suh, MD||Seoul National University Department of Dermatology|
|Study Director:||Hyuck Hoon Kwon, MD||Seoul National University Department of Dermatology|
|Study Director:||Sun Yong Park||Seoul National University Department of Dermatology|
|Study Director:||Seounguk Min||Seoul National University Department of Dermatology|
|Study Director:||Jae Yoon Jung||Seoul National University Department of Dermatology|